Blog

Yes, a telehealth brand can run a Black Friday sale on November 27, 2026, if the discount is on what the brand actually sells (the membership, the care fee, non-prescription products) and not a promise about a prescription the clinician has not written yet. The reference price has to be real, the countdown has to be true, the ad still needs LegitScript-backed approval, and a 'first month for $X' offer is the one most likely to come back as chargebacks in January. Here is each rule, verified, with what we would run instead.

A gym can put a GLP-1 program in front of its members without employing a single prescriber, as long as the medicine stays inside a physician-owned practice and the gym sticks to what gyms are good at: coaching, training, and the member relationship. There are three workable structures (referral, co-branded program run by an MSO and PC, and a licensed brand), and the corporate practice of medicine doctrine decides which one fits your states. The strongest clinical argument for the partnership is muscle: in SURMOUNT-1, about a quarter of the weight lost on tirzepatide was lean mass.

Rock Health counted 164 digital health M&A deals in the first nine months of 2026, so buyers exist. What they pay for in a DTC telehealth brand is mostly decided on the day the founder picks a structure: a patient relationship the brand owns, a merchant account and card tokens in its own name, retention cohorts it can prove, a clean MSO and PC arrangement, and no revenue that depends on compounded GLP-1 or on a platform it cannot leave. Here is the diligence list, in the order a buyer works through it, and what each item does to the price.

The commission model is the compliance decision in a telehealth affiliate program. A flat bounty per paid membership, revenue share on non-prescription products, and volume tiers can all work; paying partners a percentage of prescription revenue, or more for a higher dose, is the arrangement state fee-splitting and patient-brokering laws and the federal anti-kickback statute were written for. This is the brand-side playbook: models, the legal lines, FTC disclosure, a claims library, and fraud controls.

Generic sildenafil and tadalafil cost cents a tablet at a wholesale-style pharmacy, which means an ED brand earns nothing on the drug and everything on the service around it. This is the 2026 launch guide: the formulary, what the big brands charge, the intake screens that keep the program safe, and the retention problem that on-demand use creates. ED medications are not controlled substances, so the DEA's December 31 deadline does not touch this category.

Yes, for a narrower set of founders than in 2024. Rock Health counted $11.1 billion of digital health venture funding across 358 deals through Q3 2026 and 164 M&A exits, so money and buyers are both present. Margins are another story: Hims' gross margin fell from 76% to 64% on the branded shift, BetterHelp's cash-pay revenue fell 12%, and CVS sells a $29 weight-loss visit. Here is the evidence, and our view on who should start one now and who should not.

A telehealth business plan that a lender, investor or pharmacy partner will actually read has nine sections, and most of the weight sits in three: the clinical and legal structure, the unit economics, and the month the cash runs lowest. This template gives you each section with what to write in it, then fills it in for a fictional GLP-1 brand using 2026 prices ($349 branded Wegovy cash price, Wegovy pill from $149) and the same assumptions as our margin model. Every number in the example is derived on the page, so you can swap in your own.

A $4 million supplement brand went live with a GLP-1 program in five weeks this spring, ran its first cohort profitably with no paid acquisition, and within 90 days the clinical channel out-earned any single supplement product, according to the case study its platform vendor published in May. The mechanism is not complicated: a customer list that already trusts you, a clinical storefront that runs beside Shopify rather than inside its cart, and a program the customer was going to buy from Hims anyway. Here is the architecture, the programs that fit each kind of brand, the data boundary you must not cross, and the five-week plan.

Med spa owners are asking the same question in every Facebook group this fall: who are you using for GFEs and GLP-1 telehealth, and does it actually work without hiring anyone? The honest answer is that 'adding telehealth' means one of three very different things, from a $28 good-faith exam to a prescription program under your own brand, and the right one depends on who owns the medical side of your spa today. Here are the three models, the five compliance questions, the programs that fit a spa, and the workflow that runs between visits without a new hire.

LegitScript certification costs $975 to apply and $2,150 a year per website, takes anywhere from two business days on the expedited path to eleven weeks doing it yourself, and gates Meta, Google, Microsoft and TikTok ads for any telehealth brand. Founders on Reddit call the process 'confusing af', and the confusion is mostly about who does the work. Here are the nine standards, the documents, the realistic timelines, the compounded-GLP-1 problem, and what a platform can and cannot do about any of it.

A cash-pay telehealth brand in late 2026 keeps somewhere between $60 and $115 of every $149 membership after clinical, platform, processing and support costs, before marketing. At 100 patients that is a side business, at 500 it is a real company, and at 2,000 it is a company with a support team and a tax problem. Here is the model with every assumption exposed, the public-company numbers it is checked against, and the one cost decision that moves the answer more than price does.

A fitness YouTuber announced his own hormone and peptide clinic in September ('I personally selected the practitioners'), Karpa Health lists creators as a customer segment on its pricing page, and the founder who built Medvi did it, in the words of one investigation, with 800 fake Facebook accounts posing as doctors. Creator-launched health brands are the fastest-growing kind of DTC telehealth company and the easiest to get sued for. Here are the two models, the launch stack, the economics of an audience that costs nothing to acquire, and the rules that decide whether the creator is a founder or an exhibit.

CVS sells a $29 online weight-loss visit with no membership, Walgreens charges $49, Amazon One Medical charges $39 for a message and $59 for video, and by early Q4 the CVS app will show Lilly's cash prices with same-day pickup at 9,000 stores. Retail has priced the visit as a loss leader for the pharmacy. An independent brand that tries to match it is competing with a pharmacy's margin using a clinic's costs. Here is what retail does not do, the three positions that still win, and the pricing design patients told us they want.

January is the biggest demand month in DTC telehealth, and the programs that win it are built in September, not December. Provider capacity, support staffing, pharmacy commitments, ad staging, and load tests all have lead times measured in months. This is the build list, laid out on a September-to-December timeline, with the two failure points that break first: intake review queues and lead response time.

Prescription skincare is the most natural telehealth vertical for a wellness brand that already has an audience: visual results, cash-pay pricing, creator-native acquisition, and a 90-day refill rhythm that compounds. The clinical spine is photo-based async review, which means the whole program rides on the quality of the pictures your intake collects. Here is the launch playbook: the photo spec, the entry SKUs, the pharmacy decision, and the expansion path.

Weight loss is crowded, hair loss is saturated, and ED is a knife fight against national brands. Twelve telehealth business ideas still combine durable demand, thin competition, and workable unit economics. Here is each one with its demand signal, competition density, economics sketch, regulatory lift, and time to launch, the September 2026 data behind them (Wheel's age mix, the $19 billion menopause economy, GLP-1 microdosing at 14.6 percent), and who pivoted or closed this year.

Skip the guru math. Public filings and published prices are the only benchmark sources that cannot lie to you. Hims guided Q2 to $680-700M of revenue with $35-55M of adjusted EBITDA, manufacturers set cash price floors from $149 to $449, and Rock Health counted $7.4B of H1 funding with a $14M median deal. Here is what those numbers actually imply for your pricing, marketing, and retention math, and what they cannot tell a 500-patient brand.

Reddit is roughly 47 percent of Perplexity's citations, and every major assistant leans on it when a patient asks whether a health brand is legitimate. Your patients research there, your future B2B customers research there, and most telehealth brands are either invisible on the platform or getting banned from it. Here is how to participate in a way that survives moderators, compliance review, and the AI answer layer built on top.

An online TRT clinic is one of the most durable subscription businesses in DTC telehealth: a symptomatic patient, a measurable biomarker, and a therapy that works best when it never lapses. It is also one of the most demanding builds, because testosterone is a Schedule III controlled substance and the labs are not optional. Here is the operator's playbook as of September 2026: the software the clinic runs on, the lab cadence, the DEA clock (flexibilities through December 31, Special Registration rule at OIRA since August 25), the $100-200 per month bundle economics, and the retention loop.

Q2 prints are landing all week: Hims & Hers reported Monday after close, with LifeMD, Teladoc, Omada, and the rest of the cohort in the same window. We built this frame on what was confirmed going in, the guidance, the disclosed pivots, the channel data, so it holds whatever the actuals say. Five structural takeaways, plus a setup table designed for swapping the actuals in as transcripts land.